Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Jun;28(2):269-275.
doi: 10.1111/jns.12547. Epub 2023 Apr 20.

IgM anti-MAG± peripheral neuropathy (IMAGiNe) study protocol: An international, observational, prospective registry of patients with IgM M-protein peripheral neuropathies

Tatiana Hamadeh  1 , Perry T C van Doormaal  2   3 , Mariëlle H J Pruppers  1 , Johannes P M van de Mortel  2 , Janneke G J Hoeijmakers  1 , David R Cornblath  4 , Alexander F J E Vrancken  2 , Catharina G Faber  1 , Nicolette C Notermans  2 , Ingemar S J Merkies  1   5 ; IMAGiNe Consortium
Collaborators, Affiliations
Case Reports

IgM anti-MAG± peripheral neuropathy (IMAGiNe) study protocol: An international, observational, prospective registry of patients with IgM M-protein peripheral neuropathies

Tatiana Hamadeh et al. J Peripher Nerv Syst. 2023 Jun.

Abstract

Background: International consensus on IgM ± anti-MAG ± PNP (IgM PNP) is lacking. Despite increasing interest in clinical trials, validated disease-specific measures are needed to adequately capture limitations and changes over time. The IMAGiNe (IgM ± anti-myelin associated glycoprotein [MAG] peripheral neuropathy) study surges as an international collaboration to create a standardized registry of patients with IgM ± anti-MAG PNP. The consortium, which currently consists of 11 institutions from 7 countries, presents here the IMAGiNe study design and protocol.

Aims: Functional outcome measures will be constructed at the level of impairment, as well as activity and participation. We aim to describe the natural history of the cohort, the role of anti-MAG antibodies, the presence of clinical subtypes, and potential biomarkers.

Methods: The IMAGiNe study is a prospective, observational cohort study with a 3-year follow-up. At each assessment, researchers collect clinical data and subjects complete a list of preselected outcome measures. Among these, the "Pre-Rasch-built Overall Disability Scale (Pre-RODS)" questionnaire will be submitted to Rasch analysis to assess classic and modern clinimetric requirements.

Results: The final measures will include the IgM-PNP-specific RODS and Ataxia Rating Scale (IgM-PNP-ARS). Descriptions of the disease course, clinical heterogeneity, treatment regimes, variations in laboratory values, and antibody titers will help reach consensus on diagnosis and follow-up strategies.

Conclusion: The constructed interval scales will be cross-culturally valid and suitable for use in future clinical trials and daily practice. The ultimate goals are to improve functional individualized assessment, reach international consensus, and lay the foundations for successful designs in future studies.

Keywords: IgM neuropathies; anti-MAG antibodies; clinimetry; monoclonal gammopathy of undetermined significance; paraproteinemic neuropathies.

PubMed Disclaimer

References

REFERENCES

    1. Steck AJ. Anti-MAG neuropathy: from biology to clinical management. J Neuroimmunol. 2021;361:577725.
    1. Bardel B, Molinier-Frenkel V, Le Bras F, et al. Revisiting the spectrum of IgM-related neuropathies in a large cohort of IgM monoclonal gammopathy. J Neurol. 2022;269(9):4955-4960.
    1. Campagnolo M, Ruiz M, Falzone YM, et al. Limitations in daily activities and general perception of quality of life: long term follow-up in patients with anti-myelin-glycoprotein antibody polyneuropathy. J Peripher Nerv Syst. 2019;24(3):276-282.
    1. Kyle RA, Dyck PJ. Neuropathy associated with the monoclonal Gammopathies. In: Dyck PJ, Thomas PK, eds. Peripheral Neuropathy. 4th ed. Elsevier Saunders; 2005:2255-2276.
    1. Yeung KB, Thomas PK, King RH, et al. The clinical spectrum of peripheral neuropathies associated with benign monoclonal IgM, IgG and IgA paraproteinaemia. Comparative clinical, immunological and nerve biopsy findings. J Neurol. 1991;238(7):383-391.

Publication types